Prenatal genetic screening statistics: what a high-risk cell-free DNA result actually means

She was 28, low-risk by every checklist, and the lab report still said "high risk" for a microdeletion she had never heard of. The paper used the word "positive." Her husband read it as a diagnosis. By the time they sat in my office, three sleepless nights later, they had already googled outcomes, support groups, and termination timelines. The confirmatory amniocentesis came back normal two weeks after that.

That sequence is not rare. Cell-free DNA screening, often called NIPT or NIPS, is an excellent screening test for the common trisomies. It is not a diagnosis. The gap between those two sentences is where most of the clinical harm happens. The numbers that close it are positive predictive value, false-positive rates for rare conditions, and whether diagnostic follow-up actually occurs.

This page gathers primary figures a reporter, clinician, or parent can lift with the source named beside them: detection rates, PPV by age and condition, microdeletion performance, and uptake by coverage status.

Maternal age	Prevalence of T21 at 16 weeks	PPV
20 years	1 in 1,177	68%
25 years	1 in 1,040	71%
30 years	1 in 700	78%
35 years	1 in 296	89%
40 years	1 in 86	97%

Source: LeFevre & Sundermeyer, American Family Physician, 2020 (Table 4), calculated from Gil et al. 2017 sensitivity 99.7% / false-positive rate 0.04% and California Department of Public Health prevalence data.

Condition	True positives / positive screens	PPV
Trisomy 21	228 / 268	85%
Trisomy 18	82 / 106	77%
Trisomy 13	34 / 76	45%
Monosomy X	24 / 89	27%
22q11.2 deletion	n/a	21%
1p36 deletion	n/a	14%
Cri-du-chat / Prader-Willi-Angelman	n/a	0%
Microdeletion regions overall	7 / 52	13.4%

Source: Petersen et al., American Journal of Obstetrics & Gynecology, 2017. Microdeletion denominators reflect cases with confirmatory testing at a large referral genetic diagnostic laboratory.

What cell-free DNA screening actually is

Cell-free DNA screening analyzes short fragments of DNA circulating in maternal blood. Most are maternal. A minority (typically a few percent to the low teens, depending on gestational age and maternal weight) come from placental trophoblast. Laboratories sequence or count those fragments and look for over- or under-representation of chromosomes 21, 18, and 13, and often sex chromosomes. Expanded panels add selected microdeletion regions.

ACOG Practice Bulletin No. 226, published with the Society for Maternal-Fetal Medicine in 2020, states that cell-free DNA is the most sensitive and specific screening test for the common fetal aneuploidies and can be performed any time after about 9-10 weeks. The same bulletin says screening and diagnostic testing should be offered to all pregnant patients regardless of age or baseline risk, and that every patient has the right to decline.

That "screening, not diagnostic" line is not legal fine print. The DNA being counted is largely placental. Confined placental mosaicism, vanishing twin, maternal copy-number variation, and technical limits all produce false positives. A high-risk result changes the prior probability; it does not establish the fetal karyotype. Confirmation still requires chorionic villus sampling or amniocentesis when a definitive answer is wanted.

Chromosomal abnormalities occur in roughly 1 in 150 live births, according to ACOG. Trisomy 21 is the most common autosomal aneuploidy among liveborn infants, at about 1 in 700. Copy-number variants are different: ACOG notes they occur in about 0.4% of pregnancies and, unlike the common trisomies, do not rise with maternal age. That is why expanded panels are marketed to young patients, and why the math of PPV gets harsh for rare targets.

Detection rates for the common trisomies

The cleanest pooled numbers still come from Gil and colleagues' 2017 updated meta-analysis in Ultrasound in Obstetrics & Gynecology. Across nearly 2,000 trisomy 21 cases and more than 220,000 non-trisomy-21 singleton pregnancies, the weighted detection rate was 99.7% (95% CI 99.1-99.9%) with a false-positive rate of 0.04% (95% CI 0.02-0.07%). For trisomy 18, detection was 97.9% at a 0.04% false-positive rate. For trisomy 13, detection was 99.0% at a 0.04% false-positive rate. Combining the three common trisomies, the authors estimated a false-positive rate on the order of 0.13%.

Head-to-head evidence in a routine prenatal population is the Norton et al. 2015 trial in the New England Journal of Medicine. Among 15,841 women with results available (mean age 30.7 years, mean gestational age 12.5 weeks), cell-free DNA detected all 38 cases of trisomy 21 (sensitivity 100%; 95% CI 90.7-100), compared with 30 of 38 (78.9%) for standard first-trimester screening. The false-positive rate was 0.06% for cell-free DNA versus 5.4% for standard screening. Positive predictive value was 80.9% versus 3.4%.

For trisomy 21 in a general population, cell-free DNA is not a little better than serum screening. It is a different category of test. The residual problem is not sensitivity; it is what a positive means when the condition is uncommon. The SMART program later reported SNP-based performance with genetic confirmation (Dar et al., AJOG 2022): trisomy 21 PPV was 85.7% in the low-risk group and 97.5% in the high-risk group; for all three common trisomies combined, 74.3% and 94.2%. Prevalence drove PPV.

PPV depends on age and prevalence

Positive predictive value is the probability that a high-risk screening result is a true positive. It is not a fixed property of the assay. It moves with prevalence. Because trisomy 21 risk rises with maternal age, the same sensitivity and specificity produce different PPVs at different ages.

Using the Gil 2017 performance estimates (99.7% sensitivity, 0.04% false-positive rate) and California midtrimester prevalence figures, LeFevre and Sundermeyer published a counseling table in American Family Physician in 2020. At age 20, PPV for trisomy 21 was 68%. At 25, 71%. At 30, 78%. At 35, 89%. At 40, 97%. For a 20-year-old with a high-risk result for Down syndrome, roughly one in three positives is still a false positive. For a 40-year-old, nearly all are true positives.

ACOG's age table in Practice Bulletin No. 226 shows the prevalence engine. At age 20, second-trimester trisomy 21 risk is about 8 per 10,000 (1 in 1,250). At 35 it is about 34 per 10,000 (1 in 294). At 40 it is about 116 per 10,000 (1 in 86). Prevalence multiplies almost fifteenfold from 20 to 40, and PPV climbs with it.

Young patients should not avoid the test. ACOG and the American College of Medical Genetics and Genomics both support offering cell-free DNA as a first-line screen regardless of age. ACMG's 2023 guideline strongly recommends NIPS over traditional serum methods for trisomies 21 and 18 (and for 13) in all singleton and twin pregnancies. A high-risk result in a 25-year-old still needs more careful language than the same result in a 41-year-old, and both need diagnostic confirmation before irreversible decisions. Families comparing age-related fertility decline with aneuploidy risk often land in the same visit; our review of fertility and age statistics covers that half of the conversation.

Microdeletions and the false-positive problem

This is where the public story about false positives is mostly correct, and where laboratory marketing has sometimes outrun the evidence.

Petersen and colleagues at a large U.S. referral genetic diagnostic laboratory published confirmatory-testing PPVs in AJOG in 2017. Among positive cell-free DNA results with diagnostic follow-up, PPV was 85% for trisomy 21, 77% for trisomy 18, and 45% for trisomy 13. Monosomy X sat at 27%. For microdeletion regions, PPVs ranged from 0% for Cri-du-chat and Prader-Willi/Angelman to 14% for 1p36 deletion and 21% for 22q11.2 deletion. Across microdeletion positives with confirmatory data, only 7 of 52 were true positives (a 13.4% overall PPV).

Schwartz et al. (2018) reported follow-up of positive microdeletion results from multiple NIPT vendors. In low-risk positives, only 25 of 335 were confirmed, a PPV of 7.4%, including about 6.6% for 22q11.2. When the condition is rare enough, a highly specific test still generates more false alarms than true cases.

22q11.2 deletion syndrome is the partial exception because it is the most common pathogenic microdeletion. The SMART study (Dar et al., AJOG 2022) enrolled 20,887 women at 21 centers; genetic outcome was available for 18,289. Twelve cases of 22q11.2DS were confirmed, a prevalence of 1 in 1,524. The primary algorithm detected 9 of 12 (sensitivity 75.0%) with a PPV of 23.7%. An updated algorithm detected 10 of 12 (83.3%) with a false-positive rate of 0.05% and a PPV of 52.6% (10 of 19). Even then, roughly half of high-risk results were false positives.

ACMG's 2023 guideline includes a conditional recommendation to offer NIPS for 22q11.2 deletion to all pregnancies. That is not an endorsement of expanded multi-microdeletion panels. ACOG and SMFM have been more cautious about routine expanded screening because PPV collapses as targets get rarer. In April 2022 the FDA warned that genetic noninvasive prenatal screens can produce false results, are not diagnostic, and that advertising claims of being "reliable" or "highly accurate" may not hold for all marketed conditions. The agency's concern was rare-condition screening and families acting on a screen alone.

Clinical translation: a high-risk result for trisomy 21 in a 39-year-old is usually a true positive and still needs confirmation if management will change. A high-risk result for a rare microdeletion in a 27-year-old is usually a false positive and still needs confirmation if management will change. Same verb. Different priors.

Uptake and who gets offered the test

National U.S. uptake is hard to pin to a single percentage because cell-free DNA is ordered through dozens of commercial laboratories, billed under evolving codes, and covered differently by payers and states. Population snapshots still show who gets the test when it is available.

Ellison and colleagues analyzed the 2015 Massachusetts All-Payer Claims Database for pregnant patients aged 35 or older (the group then covered under both Medicaid and commercial plans in a high-coverage state). Overall uptake was 201.2 NIPT tests per 1,000 eligible patients, or about 20%. The insurance split was stark: 48.7 per 1,000 among Medicaid enrollees versus 272.1 per 1,000 among commercial enrollees. In adjusted models, Medicaid was associated with an odds ratio of 0.18 (95% CI 0.16-0.20). Zip codes with higher shares of Black or Hispanic residents and higher poverty also had lower uptake after adjustment.

That is a best-case state in an early-diffusion year, and the disparity still ran more than fivefold by payer. Equal coverage on paper did not produce equal use. ACOG's 2020 bulletin moved toward offering cell-free DNA to all patients; ACMG's 2023 guideline strongly recommended NIPS as first-line for the common trisomies. As recommendations diffuse into payer policy, the equity question is whether uptake rises evenly.

Patients who arrive late to prenatal care, or who are still sorting cycle timing and pregnancy dating, often miss the early counseling window. Tools such as our ovulation calculator and implantation timing guide are not substitutes for genetic counseling, but they are the questions many people ask before they ever hear "cell-free DNA."

After a high-risk result

Professional guidance is consistent: a high-risk cell-free DNA result should prompt genetic counseling and the offer of diagnostic testing. No major society treats the screen as definitive for decisions that depend on a confirmed diagnosis.

Diagnostic options are chorionic villus sampling, typically between 10 and 13 weeks, and amniocentesis after 15 weeks. ACOG material cited in the family-medicine review of this topic estimates procedure-related pregnancy-loss risk at about 1 in 455 for CVS and 1 in 900 for amniocentesis. Those figures are lower than older textbook numbers, not zero, and they are the reason a screen with a 0.04% false-positive rate still matters: it spares most patients an invasive procedure.

Not everyone who screens high-risk proceeds to diagnosis. Some decline because they would not change management. Some cannot access a timely appointment. Some have acted on the screen alone, a practice ACOG and the FDA (along with ACMG) discourage. Incomplete follow-up also biases published PPV estimates.

A "no-call" or failed result is a separate problem. Low fetal fraction is more common with higher maternal weight and earlier gestational age. AAFP's review notes that 50% to 80% of no-call results yield a reportable result on redraw. Norton's NEJM cohort and other series found higher aneuploidy prevalence among failed tests, so a no-call is not simply "try again later" without further risk assessment or diagnostic options. Background pregnancy loss is far more common than procedure-related loss; our summary of miscarriage and pregnancy-loss statistics puts those baseline rates in context.

Discordant results (high-risk cell-free DNA with normal diagnostic testing) point to confined placental mosaicism, vanishing twin, maternal chromosomal findings, or, rarely, maternal malignancy. Those cases need specialist genetics input rather than a second commercial screen ordered in parallel.

Cost, coverage, and access

Coverage, not list price, usually decides whether a patient gets the test. KFF's 2021 state Medicaid survey found that 38 of 40 responding states covered first-trimester genetic screening for pregnant enrollees, often with prior authorization or medical-necessity rules. Several states described specific requirements for cell-free DNA; Nevada reported that it did not cover cell-free DNA tests. All responding states covered amniocentesis. Most (39 of 42) covered CVS; Alabama, Indiana, and Mississippi reported no CVS coverage. Genetic counseling was covered in 32 of 42 responding states.

Those figures predate some later expansions, but they show the unevenness: one state Medicaid program may cover the most accurate screen while another routes patients through serum analytes. Commercial plans also vary for average-risk patients and for expanded microdeletion panels. Self-pay cash prices commonly land in the low hundreds of dollars through laboratory assistance programs; full list charges are often higher. Deductibles and out-of-network labs still produce surprise bills, and Medicaid enrollees are often excluded from manufacturer financial-assistance programs even when state coverage is incomplete.

The access pattern rhymes with other perinatal services that depend on specialty labs and prior authorization. The same architecture shows up in maternity care deserts and provider shortages and in broader women's healthcare access disparities: coverage on a benefits grid is necessary and not sufficient. For patients building a pregnancy timeline around IVF, the IVF due-date calculator helps when gestational age is counted from transfer; accurate dating matters because cell-free DNA before about 9-10 weeks fails more often.

The policy direction is clear. ACMG wants NIPS as first-line common-trisomy screening. ACOG wants every patient offered screening and diagnostic options with PPV counseling. FDA wants marketing claims reined in for rare conditions. The unfinished work is equal pretest counseling and equal access to the best screen and to diagnostic confirmation. Nobody should confuse a 13% PPV microdeletion flag with a diagnosis.

The couple from the opening left with a normal microarray and residual anger that three nights of terror had been avoidable with one clearer sentence on the report. That sentence is the point of these numbers.

Frequently asked questions about prenatal genetic screening

Is cell-free DNA (NIPT) a diagnostic test?

No. Cell-free DNA is a screening test. ACOG, SMFM, ACMG, and the FDA all state that high-risk results require confirmatory diagnostic testing (CVS or amniocentesis) before they are treated as a fetal diagnosis. The DNA analyzed is largely placental, so mosaicism and other biological factors can produce false positives.

How accurate is NIPT for Down syndrome?

Gil and colleagues' 2017 meta-analysis estimated a 99.7% detection rate and 0.04% false-positive rate for trisomy 21 in singleton pregnancies. In the Norton et al. NEJM trial, PPV was 80.9% in a routine prenatal population, versus 3.4% for standard first-trimester screening. PPV still varies with maternal age.

What is the positive predictive value at my age?

Published counseling tables using Gil performance estimates show trisomy 21 PPV of about 68% at age 20, 78% at 30, 89% at 35, and 97% at 40. Younger patients have more false positives after a high-risk result because baseline prevalence is lower. Ask for a result-specific PPV when possible.

Why are microdeletion results more often false positives?

Rarity. Even a highly specific test generates more false alarms than true cases when the condition is uncommon. Petersen et al. (2017) found an overall microdeletion-region PPV of 13.4%, with 0% for some conditions and 21% for 22q11.2. Schwartz et al. (2018) reported 7.4% among low-risk microdeletion positives.

Does Medicaid cover NIPT?

It depends on the state and medical-necessity rules. In KFF's 2021 survey, most responding states covered first-trimester genetic screening, but several required prior authorization, and Nevada reported no cell-free DNA coverage. Diagnostic procedures were more consistent: all responding states covered amniocentesis and 39 of 42 covered CVS.

What should I do after a high-risk NIPT result?

Seek prompt genetic counseling and discuss diagnostic options. Do not make irreversible pregnancy decisions on the screen alone. Ultrasound can add context, but only CVS or amniocentesis can confirm the fetal chromosomal result. Ask for the condition-specific positive predictive value, not a generic accuracy percentage.